NCT00570349 - Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Cystic Fibrosis

Interventions

DRUG

Nitric Oxide for Inhalation

Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.

DRUG

Nitric Oxide for Inhalation

Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.

DRUG

Nitrogen

100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.

Trial Locations (1)

The Children's Hospital, Denver